Introduction
============

*Candida* endocarditis is an infrequent disease with a high mortality rate, ranging within 23-46%. This disease is commonly reported in patients with cardiac valve replacement \[[@B1], [@B2]\]. The potentiality of *Candida* species, mainly *Candida albicans,* to form biofilms on native cardiac tissue and prosthetic valve causing increasing resistance to antifungal treatment, has a great impact on patient outcomes \[[@B3]\]. As *Candida* species have various degrees of susceptibility to currently available antifungals, it is very important to identify the causative agents and prescribe the effective treatment \[[@B3]\].

The major risk factors for this condition include indwelling central venous catheters, long-term broad-spectrum antibacterial therapy, and previous heart surgery. Other risk factors, such as long-term usage of corticosteroids, cytotoxic drug consumption, intravenous drug abuse, and immunosuppression, are implicated as the causes of increasing the incidence of fungal endocarditis \[[@B4], [@B5]\]. In recent years, the emergence of drug-resistant *Candida* species has complicated the treatment of different diseases and adoption of the proper medication regimen.

Herein, we reported a case of *Candida* prosthetic valve endocarditis (PVE) caused by multi-azole and amphotericin B resistance in a patient with myelodysplasia syndrome (MDS) for the first time in Iran. We also briefly reviewed the reports of PVE caused by *Candida*species in patients with different types of cancers.

Case report
===========

A 70-year-old woman with a severe headache, vertigo, fever, and arrhythmia, suspected with Parkinson\'s disease was admitted to Mazandaran Heart Center, Sari, north of Iran, in 2017. She had a history of symptomatic sever mitral stenosis probably due to rheumatic heart disease in her childhood for which she underwent mitral commissurotomy when she was 25 years old. After her first surgery, she administered penicillin G benzathine 1.2 million units IM once a month up to her last admission. She was also subjected to echocardiography every 6 months.

In 2010, the patient suffered from persistent fever, which was unresponsive to antibiotics for 2 weeks. Echocardiography revealed infective endocarditis; however, no microbial strain was isolated from blood culture. After treatment, symptoms reduced; nonetheless, a few days after discharging from the hospital, her blood cell profile was deteriorated gradually. The diagnosis of MDS was eventually confirmed after performing bone marrow aspiration for three times. Thereafter, the patient was subjected to androgen therapy with danazol (10 mg/kg b.w./day), and Prednisolone (1 mg/kg b.w./day). When the white blood cell count became normal, danazol was discontinued; however, the consumption of prednisolone (5 mg/day) was continued. During the long-term use of prednisolone, she was afflicted with steroid-induced diabetes and oral lichen planus due to the impairment of immune system.

On October 2015, due to the deterioration of patient\'s general condition, she was transferred to Tehran Heart Center for further evaluation. Transesophageal echocardiography (TEE) revealed severe mitral valve (MV) stenoses; as a result, she was subjected to percutaneous transvenous mitral commissurotomy.

On May 2016, the patient was admitted to hospital due to persistent fever and general weakness, and was detected with MV regurgitation. She was prescribed vancomycin (20 mg/kg), gentamicin (1 mg/kg), and ciprofloxacin (10 mg/kg). She had a fever of up to 40°C that was unresponsive to antibiotics and persisted after a week. Imipenem was replaced with ciprofloxacin and continued for 6 weeks. The TEE showed mobile MV vegetation that involved more than 3/4 of the valves. Therefore, the patient underwent MV replacement with a biological (porcine) prosthetic valve.

Following the use of broad-spectrum antibiotics, she was diagnosed with *Candida* onychomycosis and recurrent *Candida*vulvovaginitis, and therefore prescribed fluconazole (150 mg) for 3 weeks and caspofungin (intravenous \[IV\]; 50 mg three times a day) for 6 weeks, coupled with vancomycin and gentamicin.

On February 2017, she presented flu-like symptoms, such as fever and chills, dizziness, severe headache, and heart arrhythmias for 5 days prior to hospital admission. She was admitted to the Cardiac Care Unit of Mazandaran Heart Center in Sari and prescribed ceftizoxime (IV, 500 mg). Echocardiography revealed a large vegetation on the MV annulus.

Two consecutive blood samples were obtained from the patient and inoculated into biphasic brain heart infusion medium. After one week of incubation at 37°C, the blood cultures were positive. The yeast isolate was presumptively identified as *C. albicans* using conventional methods including chlamydospore production test, germ tube test, and appearance on CHROMagar *Candida*.

On March 2017, the patient's condition deteriorated. The blood cultures were negative. She underwent the second prosthetic valve replacement. The surgery revealed the formation of huge fungal white and creamy vegetation and abscess overall the prosthetic valve. The explanted valve and vegetation were sent to laboratory for further evaluations. Direct examination (KOH 20%) and calcofluor white staining of the sample showed lots of budding yeast cells.

To identify the species, the yeast colonies were yielded on Sabouraud dextrose agar medium after a 24-hour incubation at 27ºC. The isolated yeast was identified as *Candida albicans* using the conventional methods. The diagnosis was confirmed by polymerase chain reaction (PCR) assay using the two universal primers, namely ITS1 and ITS4 \[[@B6]\]. The amplicons were sequenced and compared with the GenBank database; then, they were submitted to GenBank and received accession number MG763751.

Amphotericin B, deoxycolate (1 mg/kg/day), caspofungin (70 mg/kg on the first day and 50 mg/kg in the next days), and voriconazole (6 mg/kg bid on the first day and 4 mg/kg bid in the next days) together with broad-spectrum antibiotics, including vancomycin (20 mg/kg bid) and gentamicin (1 mg/kg bid) were administered. However, 48 h later, the patient presented with dyspnea, decreased consciousness, and decreased blood cells, resulting in a coma. The patient passed away due to sepsis probably related to the candidemia and *Candida* PVE with antifungal-resistant *Candida* *albicans.*

In vitro antifungal susceptibility testing of *Candida* *albicans* isolate was carried out based on the clinical and laboratory standards institute (CLSI) M27-A3 \[[@B7]\] and M27-S4 guidelines \[8\]. Based on the breakpoint, the isolate was resistant to voriconazole (16 μg/ml), itraconazole (16 μg/ml), fluconazole (64 μg/ml), posaconazole (16 μg/ml), and amphotericin B (4 μg/ml). Furthermore, it was susceptible to anidulafungin (0.008 μg/ml) and micafungin (0.008 μg/ml), and intermediate to caspofungin (0.5 μg/ml).

***Ethical considerations***

The study protocol was approved by the Ethics Committee of Mazandaran University of Medical Sciences, Sari, Iran.

Discussion
==========

Over the past few years, there has been an increasing number of reports on fungal endocarditis \[9\] showing the high morbidity and mortality rate of this condition, ranging within 30-80% \[[@B10]\]. Although *Candida* endocarditis accounts for about 1-2% of infective endocarditis, it can be very fatal. This medical condition is usually diagnosed postmortem because of its nonspecific clinical symptoms. *C. albicans,* followed by *C. parapsilosis,* are the common *Candida*species causing endocarditis \[[@B9]\].

According to the Duke criteria, PVE is classified as \'\'early\'\' when it happens within 60 days of valve replacement and \'\'late\'\' when occuring more than 60 days post-replacement \[[@B11], [@B12]\]. In this report, our case was classified as a late *Candida* endocarditis because symptoms manifested 300 days after the first valve replacement.

In our patient, the major predisposing factors included a congenital heart disease, malignancy such as myelodysplastic syndromes (formerly described as pre-leukemia or smoldering acute leukemia), long-term use of corticosteroids for MDS treatment, prosthetic cardiac valves, and long-term broad-spectrum antibiotic therapy after cardiac surgery.

To review the cases of prosthetic valve endocarditis caused by *Candida* species in patients with different types of cancers, a search was performed on the English articles published from 1970 onward in two databases, namely Google Scholar and PubMed. The key words and medical subject headings used for the search were as follows: "*Candida* endocarditis", "Prosthetic valve endocarditis", and "Cancer". [Table 1](#T1){ref-type="table"} summarizes the demographic features, risk factors, treatment strategies, and outcomes in reported cases of prosthetic valve endocarditis caused by *Candida* species in patients with different types of cancers.

###### 

Demographic features, risk factors, treatment, and outcome in reported cases of prosthetic valve endocarditis caused by *Candida* species with different types of cancers

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Reference**             **Country**        **Age/**\                                             **Type of cancer**                  **Treatment**                          **Diagnosis method**                                               **Causative agent**    **Risk factors**                                         **Observation**                                   **Outcome**
                                               **gender**                                                                                                                                                                                                                                                                                                                            
  ------------------------- ------------------ ----------------------------------------------------- ----------------------------------- -------------------------------------- ------------------------------------------------------------------ ---------------------- -------------------------------------------------------- ------------------------------------------------- -------------
  Ihde, 1978 \[13\]         USA                \<20/ NS                                              Lymphoma, carcinoma of the cervix   Corticosteroids, antibiotics           B/C(+),CSF/C (+), Microscopic examination                          *C. albicans*          Chemotherapy, central venous catheter, corticosteroids   Abscesses in the left ventricular myocardium      Died

  Maeno, 1990 \[14\]        Japan              83/ NS                                                Pancreatic cancer                   Anti-fungal agents                     B/C (+), mannan antigenemia, D-arabinitol creatinine ratio, Echo   *C. albicans*          NS                                                       Vegetation at the aortic valve                    Died

  Johnston, 1991 \[15\]     USA                31/M                                                  Testicular carcinoma                5-FC+AMB, surgery                      B/C (+), TEE                                                       *C. albicans*          recurrent embryonal cell testicular carcinoma            Mitral valve vegetation                           Died

  Hamada, 1996 \[16\]       Japan              63/M                                                  Gastric cancer                      Anti-fungal agents, surgery            B/C(+)                                                             *C. albicans*          liver abscess                                            Aortic and tricuspid regurgitation                Survived

  65/M                      Bile duct cancer   Anti-fungal agents, catecholamine, digoxin, surgery   B/C(+)                              *C. albicans*                          NS                                                                 Aortic regurgitation   Died                                                                                                       

  Inoue, 1998 \[17\]        Japan              57/M                                                  Gastric cancer                      FLC, surgery                           NS                                                                 *C. parapsilosis*      Chemotherapy, central venous catheter                    Cardiac valve vegetation                          Survived

  Ariffin, 1999 \[18\]      Malaysia           \<1/NS                                                ALL                                 AMB , FLC                              Echo                                                               *C. albicans*          Immunodeficiency                                         NS                                                NS\*

  Jagernauth, 2007 \[19\]   UK                 54/M                                                  Carcinoid disease                   Antifungal drug, Surgery               NS                                                                 *Candida*spp           Surgery for pulmonary and tricuspid valve replacement    Vegetation                                        Survived

  Ozkiraz, 2007 \[20\]      Turkey             \<1/ NS                                               AML                                 FLC, AMB , surgery                     Echo, B/C(+), pathological\                                        *C. albicans*          NS                                                       Vegetation at the outlet of the right ventricle   Died
                                                                                                                                                                                examination                                                                                                                                                                                          

  Block, 2009 \[21\]        Australia          64/F                                                  Carcinoma of the lung               FLC, 5FC\                              B/C (+), U/C(+), TEE                                               *C. albicans*          NS                                                       Fungal ball                                       Survived
                                                                                                                                         thrombolytic therapy, surgery                                                                                                                                                                                                               

  Chopra, 2010 \[22\]       USA                74/F                                                  Cardiomyopathy                      MFG, surgery                           B/C, U/C(+), TEE                                                   *C. kefyr*             Diabetes type II                                         Mitral valve vegetation                           Survived

  Reyes, 2015 \[23\]        Peru               36/F                                                  Ovarian cancer                      AFG, VRC , FLC, antibiotics, surgery   B/C(+), TEE                                                        *C. parapsilosis*      Chemotherapy                                             Vegetation in the aortic valve                    Survived

  Present case              Iran               70/F                                                  MDS                                 AMB deoxycolate, CAS, VRC              B/C(+), TEE                                                        *C. albicans*          Spectrum antibiotic therapy, diabetes                    Mitral valve vegetation                           Died
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ns: not specified, TTE: transthoracic echocardiography, TEE: transesophageal echocardiography, ALL: acute lymphoblastic leukemia, MDS: myelodysplasia syndrome, Echo: echocardiography, FLC: fluconazole, AMB: amphotericin B, AFG: anidulafungin, CAS: caspofungin, VRC: voriconazole, MFG: micafungin, 5FC: flucytosine, B/C: blood culture, U/C: urine culture, CSF: cerebrospinal fluid culture

The main factor that made treatment unresponsive was associated with multi-azole and amphotericin B-resistant *Candia*endocarditis. Multiple risk factors in our patient might be more likely to cause fungal endocarditis and have a fatal outcome. The combination of risk factors, clinical features, and echocardiography findings may help the clinical diagnosis of endocarditis. The TEE is a modality of choice with high sensitivity (87-100%) and specificity (83-94%) in the initial evaluation of the patients with high risk for infective endocarditis \[[@B24]\].

The blood culture as a traditional gold standard for the detection of candidemia has some limitations, including low sensitivity and high turnaround time \[[@B25]\]. Blood culture was positive in the first valve replacement surgery, but it was negative in the second one, while TEE showed a large vegetation on the mitral valve leading to endocarditis. The accurate diagnosis of *Candida*endocarditis is a challenge since its symptoms are very similar to those of bacterial infections. Negative blood culture results can lead to delayed anti-fungal therapy that contributes to an increased risk of hospital mortality. This explains why most of *Candida* PVE cases are diagnosed on autopsy or very late \[[@B2]\].

*Candida* species have wide ranges of virulence factors, such as adhesion, invasion, and biofilm formation on medical devices, such as biotic or artificial cardiac valves. They can have detrimental effects on patient\'s life, because they lead to the failure of the prostheses and result in the persistent presence of organism in bloodstream as a source of fungemia episodes \[[@B26]\].

Azole-resistant *Candida* species is regarded as a considerable problem for patients undergoing long-term fluconazole treatment. There are only four drug classes for *Candida* infections, including azoles, polyenes, echinocandins, and pyrimidine analogue of cytosine (5-fluorocytosine). Multidrug-resistance is defined as the non-susceptibility of the isolate to ≥ 1 agent in ≥ 2 antimicrobial categories \[[@B27]\].

In this case, we reported *C. albicans* that was resistant to multi-azoles and amphotericin B.

Hematologic disorders, such as MDS, are reported as risk factors for invasive *Candida* infections \[[@B28]\]. Long-term use of corticosteroids for the treatment of MDS and prolonged use of broad-spectrum antibiotics (e.g., penicillin over 35 years) can severely lead to the conditions predisposing a patient to candidemia and *Candida* endocarditis. Candidemia after heart valve replacement is a powerful predictive factor for late PVE, even more than one year, after the first episode of infection. Therefore, patients should be checked with an extended follow-up.

*Candida*endocarditis is an uncommon but devastating infection that affects the elderly with a weakened immune system as a late consequence of prosthetic valve replacement. The extended follow-up visits, early diagnosis, repeating valve replacement surgeries, and timely selective antifungal treatments are warranted.

Conclusion
==========

This report highlighted that *Candida* PVE can occur as a late consequence of valve replacement in elderly patient with suppressed immune system. The extended follow-up visits, early diagnosis, repeating valve replacement surgeries, and timely selective antifungal treatments are warranted.
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